Pub Date : 2022-05-05DOI: 10.4274/turkderm.galenos.2022.68638
S. Yaylı
{"title":"Topical therapies","authors":"S. Yaylı","doi":"10.4274/turkderm.galenos.2022.68638","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.68638","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46032876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-05DOI: 10.4274/turkderm.galenos.2022.77675
E. Koc, E. Bülbül Başkan
{"title":"Combination therapies in psoriasis","authors":"E. Koc, E. Bülbül Başkan","doi":"10.4274/turkderm.galenos.2022.77675","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.77675","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49421411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-05DOI: 10.4274/turkderm.galenos.2022.81594
S. Alper, E. Koc
{"title":"Use of biological agents","authors":"S. Alper, E. Koc","doi":"10.4274/turkderm.galenos.2022.81594","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.81594","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42419464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-05DOI: 10.1007/springerreference_38104
Nahide Onsun
{"title":"Cyclosporine","authors":"Nahide Onsun","doi":"10.1007/springerreference_38104","DOIUrl":"https://doi.org/10.1007/springerreference_38104","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41791634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-05DOI: 10.4274/turkderm.galenos.2022.06978
E. Bülbül Başkan
{"title":"Biosimilars","authors":"E. Bülbül Başkan","doi":"10.4274/turkderm.galenos.2022.06978","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.06978","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43648437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-22DOI: 10.4274/turkderm.galenos.2021.36604
Gülbin Yaşar, A. Bilgic, E. Yılmaz
Background and Design: Atopic dermatitis (AD) is a common chronic, recurrent, and itchy inflammatory skin disease. Various therapeutic agents are available, but severe side effects may limit their usage. Recently, dupilumab, a human monoclonal antibody that targets the interleukin-4 (IL-4) receptor alpha subunit of heterodimeric IL-4 and IL-13 receptors, is approved and might be used in patients with resistant AD, with the permission of the Ministry of Health. Materials and Methods: This study aimed to retrospectively evaluate the clinical characteristics of patients and dupilumab treatment responses in our center. This study included patients with AD who were unresponsive to conventional treatments and treated with dupilumab. Sociodemographic, laboratory data, previous treatments, and responses along with disease severity scores [eczema area and severity index (EASI)] before and after dupilumab were evaluated through the electronic files of patients. Results: A total of 21 patients (13 males and 8 females) between June 2019 and March 2021 were identified. The mean age of patients was 40.57±15.21 years. The mean duration of dupilumab treatment was 6.59±5.88 months. The mean EASI score at the beginning of dupilumab was 15.35±8.03, whereas 4.6±2.9 after treatment. A 70-100% improvement was found in approximately 75% of the patients. No side effects were observed that required treatment discontinuation or dose changes. Conclusion: Our study has the highest number of reported patients in our country, which revealed that dupilumab is highly effective and safe for conventional treatment-resistant AD.
{"title":"Dupilumab for atopic dermatitis treatment: A single-center retrospective study","authors":"Gülbin Yaşar, A. Bilgic, E. Yılmaz","doi":"10.4274/turkderm.galenos.2021.36604","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.36604","url":null,"abstract":"Background and Design: Atopic dermatitis (AD) is a common chronic, recurrent, and itchy inflammatory skin disease. Various therapeutic agents are available, but severe side effects may limit their usage. Recently, dupilumab, a human monoclonal antibody that targets the interleukin-4 (IL-4) receptor alpha subunit of heterodimeric IL-4 and IL-13 receptors, is approved and might be used in patients with resistant AD, with the permission of the Ministry of Health. Materials and Methods: This study aimed to retrospectively evaluate the clinical characteristics of patients and dupilumab treatment responses in our center. This study included patients with AD who were unresponsive to conventional treatments and treated with dupilumab. Sociodemographic, laboratory data, previous treatments, and responses along with disease severity scores [eczema area and severity index (EASI)] before and after dupilumab were evaluated through the electronic files of patients. Results: A total of 21 patients (13 males and 8 females) between June 2019 and March 2021 were identified. The mean age of patients was 40.57±15.21 years. The mean duration of dupilumab treatment was 6.59±5.88 months. The mean EASI score at the beginning of dupilumab was 15.35±8.03, whereas 4.6±2.9 after treatment. A 70-100% improvement was found in approximately 75% of the patients. No side effects were observed that required treatment discontinuation or dose changes. Conclusion: Our study has the highest number of reported patients in our country, which revealed that dupilumab is highly effective and safe for conventional treatment-resistant AD.","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42153746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-22DOI: 10.4274/turkderm.galenos.2021.26235
M. Kuş, Perihan Öztürk, H. Nazik, M. Mülayim, Tutku Bulut, Esra Rabia Akgüç, S. Koçarslan
Coronavirus disease-2019 (COVID-19) has been associated with multiple skin lesions as well as causing common respiratory symptoms. We presented a case of pityriasis rubra pilaris that developed after COVID-19 infection and treated with anti-tumor necrosis factor (adalimumab), which was not previously reported in an adult.
{"title":"Pityriasis rubra pilaris developing after COVID-19","authors":"M. Kuş, Perihan Öztürk, H. Nazik, M. Mülayim, Tutku Bulut, Esra Rabia Akgüç, S. Koçarslan","doi":"10.4274/turkderm.galenos.2021.26235","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.26235","url":null,"abstract":"Coronavirus disease-2019 (COVID-19) has been associated with multiple skin lesions as well as causing common respiratory symptoms. We presented a case of pityriasis rubra pilaris that developed after COVID-19 infection and treated with anti-tumor necrosis factor (adalimumab), which was not previously reported in an adult.","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41829755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-22DOI: 10.4274/turkderm.galenos.2021.69797
S. Mishra, Manjunath Kadnur, Shishira R. Jartarkar, Hanumanthayya Keloji, Ritu Agarwa, Spoorthy Babu
Vaccicare Clinic, Department of Dermatology, Cuttack, India *Vydehi Institute of Medical Sciences and Research Center, Department of Dermatology, Venereology and Leprosy, Bangalore, India **Sri Devaraj Urs Medical College, Department of Dermatology, Venereology and Leprosy, Kolar, India ***Kaya Skin Clinic, Department of Dermatology, Mumbai, India Swayamsidda Mishra, Manjunath Kadnur*, Shishira R. Jartarkar*, Hanumanthayya Keloji**, Ritu Agarwal***, Spoorthy Babu*
{"title":"Correlation between serum uric acid, C-reactive protein, and neutrophil-to-lymphocyte ratio in patients with psoriasis: A case-control study","authors":"S. Mishra, Manjunath Kadnur, Shishira R. Jartarkar, Hanumanthayya Keloji, Ritu Agarwa, Spoorthy Babu","doi":"10.4274/turkderm.galenos.2021.69797","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.69797","url":null,"abstract":"Vaccicare Clinic, Department of Dermatology, Cuttack, India *Vydehi Institute of Medical Sciences and Research Center, Department of Dermatology, Venereology and Leprosy, Bangalore, India **Sri Devaraj Urs Medical College, Department of Dermatology, Venereology and Leprosy, Kolar, India ***Kaya Skin Clinic, Department of Dermatology, Mumbai, India Swayamsidda Mishra, Manjunath Kadnur*, Shishira R. Jartarkar*, Hanumanthayya Keloji**, Ritu Agarwal***, Spoorthy Babu*","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43853972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-22DOI: 10.4274/turkderm.galenos.2021.73659
Esra İnan Doğan, Özlem Yağız Aghayarov
Address for Correspondence/Yazışma Adresi: Esra İnan Doğan MD, Adıyaman University Faculty of Medicine, Department of Dermatology, Adıyaman, Turkey Phone: +90 553 852 94 20 E-mail: esranander@yahoo.com Received/Geliş Tarihi: 06.09.2021 Accepted/Kabul Tarihi: 29.11.2021 ORCID: orcid.org/0000-0002-9539-334X Cite this article as: İnan Doğan E, Yağız Aghayarov Ö. The effects of isotretinoin on the inner ear in patients with acne vulgaris. Turkderm-Turk Arch Dermatol Venereol 2022;56:17-23 Abstract
{"title":"The effects of isotretinoin on the inner ear in patients with acne vulgaris","authors":"Esra İnan Doğan, Özlem Yağız Aghayarov","doi":"10.4274/turkderm.galenos.2021.73659","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.73659","url":null,"abstract":"Address for Correspondence/Yazışma Adresi: Esra İnan Doğan MD, Adıyaman University Faculty of Medicine, Department of Dermatology, Adıyaman, Turkey Phone: +90 553 852 94 20 E-mail: esranander@yahoo.com Received/Geliş Tarihi: 06.09.2021 Accepted/Kabul Tarihi: 29.11.2021 ORCID: orcid.org/0000-0002-9539-334X Cite this article as: İnan Doğan E, Yağız Aghayarov Ö. The effects of isotretinoin on the inner ear in patients with acne vulgaris. Turkderm-Turk Arch Dermatol Venereol 2022;56:17-23 Abstract","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41417323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：